Angel Biogenics Profile
Key Indicators
- Authorised Capital ₹ 0.25 M
as on 17-07-2024
- Paid Up Capital ₹ 0.25 M
as on 17-07-2024
- Company Age 12 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 47.23%
(FY 2023)
- Profit 72.51%
(FY 2023)
- Ebitda 330.68%
(FY 2023)
- Net Worth 46.59%
(FY 2023)
- Total Assets 27.92%
(FY 2023)
About Angel Biogenics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.25 M and a paid-up capital of Rs 0.25 M, as per Ministry of Corporate Affairs (MCA) records.
Renuka Sureja and Sugamkumar Sureja serve as directors at the Company.
- CIN/LLPIN
U24230GJ2012PTC070913
- Company No.
070913
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Jun 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Rajkot, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Angel Biogenics Private Limited offer?
Angel Biogenics Private Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Cardiovascular Drugs & Medication, Anticoagulant and Antiplatelet Drugs, Pain Relief Drugs & Pharmaceuticals, Anesthetic, Anti Infective Drugs & Medicines, Antibiotic Injection, Diabetes Medicine, Antibiotic Tablets, Capsule & Syrup.
Who are the key members and board of directors at Angel Biogenics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Renuka Sureja  | Director | 26-Jun-2012 | Current |
| Sugamkumar Sureja | Director | 06-Nov-2019 | Current |
Financial Performance and Corporate Structure Insights of Angel Biogenics.
Angel Biogenics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 47.23% increase. The company also saw a substantial improvement in profitability, with a 72.51% increase in profit. The company's net worth Soared by an impressive increase of 46.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Angel Biogenics?
In 2023, Angel Biogenics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Angel Surgitech Private Limited
Active 1 year 3 monthsRenuka Sureja and Sugamkumar Sureja are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Angel Biogenics?
Unlock and access historical data on people associated with Angel Biogenics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Angel Biogenics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Angel Biogenics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
